Progestogens and other Hormone Therapies in Women with Breast Cancer and Bone Metastasis
Medroxyprogesterone acetate appears to be superior to tamoxifen in breast cancer patients with bone metastasis for global response rates, but there is insufficient evidence of improved survival. Level of evidence: "B"A systematic review 1 including 10 studies with a total of 562 subjects was abstracted in DARE. Results from all four studies comparing medroxyprogesterone acetate with tamoxifen showed a statistically significant difference in global response rates in favour of medroxyprogesterone acetate. No statistically significant differences between groups were found in three studies comparing megestrol acetate with tamoxifen. One study demonstrated a statistically significant effect of medroxyprogesterone acetate as compared to megestrol acetate.
See also the breast cancer guideline of American society of oncology 2.
References
- Leriche N, Bonneterre J. [Progestational agents and bone metastasis in breast cancer] Bull Cancer 1997 Sep;84(9):891-4. [PubMed][DARE]
- Burstein HJ, Somerfield MR, Barton DL et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol 2021;39(35):3959-3977. [PubMed]